Cardiogenic Shock Treatment Market Size, Share, and Industry Analysis, By Drug Type (Inotropes, Vasopressors, Blood Thinners, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global cardiogenic shock treatment market is witnessing significant growth due to increasing prevalence of cardiovascular diseases. Some of these diseases result in cardiogenic shock, such as heart attack, atrial fibrillation, myocarditis, cardiomyopathy, and others.

• For instance, according to a study published by the National Center for Biotechnology Information (NCBI) in July 2022, the prevalence of cardiogenic shock amongst the Indian females was 4.4% and it was estimated to be 4.1% in males.

The treatments available for cardiogenic shock consist of medications and surgical procedures. There are many drugs available in the market for cardiogenic shock treatment. However, these drugs only treat the symptoms of cardiogenic shock.

Cardiogenic Shock Treatment Market Drivers

Request a Free sample to learn more about this report.

Rising Cases of Cardiovascular Diseases to Propel the Market Growth

The adoption of strenuous lifestyles is a significant contributing factor to the increasing risk of cardiovascular diseases, such as cardiogenic shock. This increase in the cases of cardiovascular conditions is leading to a higher demand for effective treatments, driving the advancements in therapeutics and investments in the market.

• According to a Cleveland Clinic report, in 2022, about 40,000 to 50,000 people get cardiogenic shock per year in the U.S.

Cardiogenic Shock Treatment Market Restraints

Limited Clinical Practices of Cardiogenic Shock Management May Limit Market Growth

The growth of the global cardiogenic shock treatment market is significantly restricted by the limited clinical practices/guidelines available for managing the condition. Although the incidence of cardiovascular diseases is on the rise, the lack of standardized and effective treatment protocols for cardiogenic shock poses major challenges. This gap in clinical practices leads to inconsistent treatment outcomes and hampers the development and adoption of innovative therapies.

• According to an article published by the National Library of Medicine in March 2019, the management of cardiogenic shock remains unstandardized despite the evidence from the numerous studies documenting its risks.

Cardiogenic Shock Treatment Market Opportunities

Rise in Research and Development Activities to Create Growth Opportunities

The initiations of research and development activities to introduce a novel drug for the treatment of cardiogenic shock is expected to significantly contribute to the market growth during the forecast period.

• In April 2023, Windtree Therapeutics, Inc. announced the publication of the company’s, “SEISMiC Pre Cardiogenic Shock Study” that examined the comparison of the administration of the two doses of istaroxime. The study reported positive results that the administration of this medication, improved the amount of blood pumped from the heart after an individual contraction and also caused considerably lower side effects.

The provision of personalized treatment based on the patient’s condition by incorporating factors such as the severity of shock and the type of cardiogenic shock, with its unchangeable risk factors for mortality, can help in making accurate clinical verdicts and predictions about the patient’s condition.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/Region, 2023


• Key Industry Developments (Mergers, Acquisitions, Partnerships)


• New Product Launches, By Key Players


• Current Treatment Practices/Guidelines for the Cardiogenic Shock Treatment


• Pipeline Analysis, By Key Players


• Impact of COVID-19 on the Market 

Segmentation

Analysis by Drug Type

Based on drug type, market is divided into inotropes, vasopressors, antiplatelet, blood thinners and others. 

The inotropes segment accounts for a substantial share of the global market as inotropes are the first line of treatment for hypotension and end-organ hypoperfusion caused by the cardiogenic shock.

• According to a June 2021 article in the European Heart Journal, the European Society of Cardiology, Heart Failure Society of America, and American College of Cardiology Foundation recommended the usage of inotropic agents for hemodynamic stabilization in the patients with cardiogenic shock.

Analysis by Route of Administration

In terms of route of administration, the market is divided into two segments, the oral and parenteral segments.

The parenteral segment accounts for a significant share of the market. The segmental growth is attributed to the development of new medications as well as the substantial usage of parenteral administration for cardiogenic shock treatment.

• For instance, 4TEEN4 Pharmaceuticals is developing a drug called Procizumab, for the treatment of cardiogenic shock, which is expected to be given through the intravenous administration.

Analysis by Distribution Channel

In terms of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies accounted for a considerable share in the global cardiogenic shock treatment market. The segmental growth is due to the requirement that the treatment for cardiogenic shock should often be undertaken in hospital settings with trained healthcare professionals. This allows the proper and safe administration of complex therapeutics and hence these medications are prescribed in these settings. Furthermore, the various pharmaceutical companies are collaborating with healthcare settings to improve the treatment of such cardiovascular diseases using the clinical algorithm.

• For instance, in September 2021, Novartis AG made a commercial agreement with NHS England. This collaboration was initiated to increase access to Leqvio, a cholesterol lowering medicine.

Regional Analysis

To gain extensive insights into the market, Request for Customization

By region, the market has been studied across Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

In terms of region, the North America accounted for a significant share in the global market. The regional market growth is attributed to the advanced healthcare infrastructure, a high prevalence of cardiovascular diseases, and significant investments in medical research and development initiatives.

• In terms of the data published by Windtree Therapeutics, Inc. in March 2023, it was observed that the average number of days attributed to hospital stays for cardiogenic shock in the U.S. was 19.6 days and the median value was 10 days. In comparison, the average length of stay for any form of hospitalization in the U.S. was 5.5 days. Hence, the cost of treatment in the U.S., which also included drugs for cardiogenic shock was considerably higher.

The Europe market accounted for a moderate share in the global market. The growth is due to the strong government support for various healthcare initiatives, which enhances the development and adoption of effective treatments.

The Asia Pacific region is expected to grow at a higher CAGR during the forecast period fuelled by the rapid expansion of healthcare infrastructure and the growing prevalence of various cardiovascular disease, which lead to cardiogenic shock treatment.

• For instance, according to an article published by theNational Heart Foundation of Australia in March 2024, more than 4.5 million people are living with cardiovascular disease in Australia.

Key Players

The global cardiogenic shock treatment market is fragmented, with the presence of large number of companies. For instance, in the U.S., Pfizer is the only manufacturer and produces about 30% of dobutamine in flexible containers. Dobutamine hydrochloride injection is a direct-acting inotropic agent that produces mild chronotropic, hypertensive, and arrhythmogenic effects compared to other drugs.

The report covers the profiles of the following key players:

• 4TEEN4 Pharmaceuticals (Germany)


• Merck & Co., Inc.  (U.S.)


• Pfizer Inc. (U.S.)


• AGEPHA Pharma FZ-LLC. (Slovakia)


• AstraZeneca (U.K.)


• Sanofi (France)


• Novartis AG (Switzerland)


• Cipla (India)


• Bayer AG (Germany)


• Lupin (India)


• Gennova Biopharmaceuticals Limited (India)

Key Industry Developments

• In January 2024, Windtree Therapeutics announced a licensed agreement with Lee’s Pharmaceuticals to develop and commercialize a positive inotropic agent called Istraoxime to improve systolic and diastolic cardiac function.


• In June 2023, AGEPHA Pharma FZ-LLC. announced that the U.S. FDA approved the utilization of colchicine under the brand name Lodoco. Reducing cardiovascular inflammation directly reduces the risk of cardiogenic shock.